Problems of using modelling in the economic evaluation of health care.

[1]  M. Drummond,et al.  Reporting guidelines for economic studies. , 1995, Health economics.

[2]  David Collett.  Modelling Survival Data in Medical Research , 1994 .

[3]  T A Sheldon,et al.  Volume and outcome in coronary artery bypass graft surgery: true association or artefact? , 1995, BMJ.

[4]  M. Egger,et al.  Who benefits from medical interventions? , 1994, BMJ.

[5]  A Briggs,et al.  Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. , 1994, Health economics.

[6]  S. Wall,et al.  Breast cancer screening with mammography: overview of Swedish randomised trials , 1993, The Lancet.

[7]  Anthony Howell,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. , 1992 .

[8]  J. Slattery,et al.  The miracle of DICE therapy for acute stroke: fact or fictional product of subgroup analysis? , 1994, BMJ.

[9]  L. Lynn,et al.  Cost effectiveness of low-dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection. , 1991, Annals of internal medicine.

[10]  M. Drummond,et al.  The DH register of cost-effectiveness studies: a review of study content and quality , 1995 .

[11]  V Torri,et al.  Beware of Surrogate Outcome Measures , 1996, International Journal of Technology Assessment in Health Care.

[12]  R B D'Agostino,et al.  Measuring effectiveness. What to expect without a randomized control group. , 1995, Medical care.

[13]  A. Feinstein.  Fraud, distortion, delusion, and consensus: the problems of human and natural deception in epidemiologic science. , 1988, The American journal of medicine.

[14]  Economics of treatment of depression. , 1995, The British journal of psychiatry : the journal of mental science.

[15]  A Briggs,et al.  Sensitivity analysis in economic evaluation: a review of published studies. , 1995, Health economics.

[16]  N Victor,et al.  "The challenge of meta-analysis": discussion. Indications and contra-indications for meta-analysis. , 1995, Journal of clinical epidemiology.

[17]  R. G. Evans.  Manufacturing Consensus, Marketing Truth: Guidelines for Economic Evaluation , 1995, Annals of Internal Medicine.

[18]  F. Song,et al.  Cholesterol lowering and mortality: the importance of considering initial level of risk. , 1993, BMJ.

[19]  R. Horwitz,et al.  "Large-scale randomized evidence: large, simple trials and overviews of trials": discussion. A clinician's perspective on meta-analyses. , 1995, Journal of clinical epidemiology.

[20]  Mark Sculpher,et al.  Economic Evaluation in Health Care Research and Development: Undertake it Early and Often , 1995 .

[21]  J. Yudkin.  How can we best prolong life? Benefits of coronary risk factor reduction in non-diabetic and diabetic subjects. , 1993, BMJ.

[22]  M. Weinstein,et al.  Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy. , 1990, Annals of internal medicine.

[23]  Bruce Kinosian,et al.  Decision Analytic Modeling: Some Uses in the Evaluation of New Pharmaceuticals , 1994 .

[24]  George Davey Smith,et al.  Misleading meta-analysis , 1995, BMJ.

[25]  P. Rochon,et al.  A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. , 1994, Archives of internal medicine.

[26]  N. Laird,et al.  Meta-analytic evidence against prophylactic use of lidocaine in acute myocardial infarction. , 1989, Archives of internal medicine.

[27]  M. Johannesson,et al.  Economic evaluation of osteoporosis prevention. , 1993, Health policy.

[28]  P. Gøtzsche.  Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal antiinflammatory drugs in rheumatoid arthritis. , 1989, Controlled clinical trials.

[29]  D G Altman,et al.  The scandal of poor medical research , 1994, BMJ.

[30]  E Frank,et al.  Cost utility analysis of maintenance treatment for recurrent depression. , 1992, Controlled clinical trials.

[31]  A. Feinstein,et al.  Improved observational method for studying therapeutic efficacy. Suggestive evidence that lidocaine prophylaxis prevents death in acute myocardial infarction. , 1981, JAMA.

[32]  A. Miller,et al.  Canadian National Breast Screening Study: 1. Breast cancer detection and death rates among women aged 40 to 49 years. , 1992, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[33]  P. Bebbington,et al.  What Price Depression? , 1994, British Journal of Psychiatry.

[34]  J. Huttunen,et al.  Efficacy of gemfibrozil in dyslipidaemic subjects with suspected heart disease. An ancillary study in the Helsinki Heart Study frame population. , 1993, Annals of medicine.

[35]  D. Torgerson,et al.  Hormone replacement therapy: compliance and cost after screening for osteoporosis. , 1995, European Journal of Obstetrics, Gynecology, and Reproductive Biology.

[36]  G A Colditz,et al.  Cost-Effectiveness and Cost-Benefit Analyses in the Medical Literature , 1992, Annals of Internal Medicine.

[37]  B Kinosian,et al.  Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. , 1991, The New England journal of medicine.

[38]  D M Eddy,et al.  The value of mammography screening in women under age 50 years. , 1988, JAMA.

[39]  A R Feinstein,et al.  Meta-analysis: statistical alchemy for the 21st century. , 1995, Journal of clinical epidemiology.

[40]  M. Drummond,et al.  Cost-effectiveness guidelines for reimbursement of pharmaceuticals: is economic evaluation ready for its enhanced status? , 1992, Health economics.

[41]  F A Sonnenberg,et al.  Toward a Peer Review Process for Medical Decision Analysis Models , 1994, Medical care.

[42]  S. Cummings,et al.  Should prescription of postmenopausal hormone therapy be based on the results of bone densitometry? , 1990, Annals of internal medicine.

[43]  J. Aboulker,et al.  Preliminary analysis of the Concorde trial , 1993, The Lancet.

[44]  S W Lagakos,et al.  Zidovudine in Asymptomatic Human Immunodeficiency Virus Infection , 1990 .

[45]  R. Lilford,et al.  Management for Doctors: Decision analysis for medical managers , 1995 .

[46]  J P Kassirer,et al.  The journal's policy on cost-effectiveness analyses. , 1994, The New England journal of medicine.

[47]  H Kragt,et al.  Importance of trends in the interpretation of an overall odds ratio in the meta-analysis of clinical trials. , 1992, Statistics in medicine.

[48]  P. Hartigan,et al.  Cost effectiveness analysis of early zidovudine treatment of HIV infected patients. , 1993, BMJ.